Literature DB >> 2030296

Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics.

G R Morrow, J Lindke, P M Black.   

Abstract

An algorithm based on learning theory and previous research for predicting which cancer patients would develop nausea in anticipation of chemotherapy treatments was tested. Patients with four or more of the following eight characteristics after their first treatment were predicted to develop anticipatory nausea (AN) by their fourth chemotherapy treatment: experienced nausea and/or vomiting after first treatment; nausea after treatment described as "moderate, severe, or intolerable;" vomiting after treatment described as "moderate, severe, or intolerable;" less than 50 yr of age; a susceptibilty to motion sickness; feeling warm or hot all over after treatment; sweating following treatment; feelings of generalized weakness following treatment. The characteristics significantly predicted subsequent anticipatory nausea development (p less than .01) by their fourth treatment in 355 consecutive cancer patients. Results were independent of the type of cancer being treated. The accuracy of the prediction was less specific than prior research, 34% of patients predicted to develop AN did so, compared to 16% of the total sample. Results are consistent with a learned etiology for the development of anticipatory side effects and support the importance of predictive methodologies in investigating mechanisms of anticipatory nausea development.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2030296     DOI: 10.1016/0885-3924(91)90011-r

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  8 in total

Review 1.  Anticipatory nausea and vomiting.

Authors:  Matti S Aapro; Alexander Molassiotis; Ian Olver
Journal:  Support Care Cancer       Date:  2004-12-15       Impact factor: 3.603

2.  Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.

Authors:  Erin M Rock; Cheryl L Limebeer; Linda A Parker
Journal:  Exp Brain Res       Date:  2014-05-04       Impact factor: 1.972

3.  Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.

Authors:  Muneer H Abidi; Nishant Tageja; Lois Ayash; Judith Abrams; Voravit Ratanatharathorn; Zaid Al-Kadhimi; Lawrence Lum; Simon Cronin; Marie Ventimiglia; Joseph Uberti
Journal:  Support Care Cancer       Date:  2011-12-23       Impact factor: 3.603

4.  Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists.

Authors:  Margarita Majem; Ma Estela Moreno; Núria Calvo; Anna Feliu; Javier Pérez; Ma Antonia Mangues; Agustí Barnadas
Journal:  Support Care Cancer       Date:  2010-11-18       Impact factor: 3.603

5.  Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life.

Authors:  Hee J Yoo; Se H Ahn; Sung B Kim; Woo K Kim; Oh S Han
Journal:  Support Care Cancer       Date:  2005-04-23       Impact factor: 3.603

6.  A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre.

Authors:  A Molassiotis; M P Saunders; J Valle; G Wilson; P Lorigan; A Wardley; E Levine; R Cowan; J Loncaster; C Rittenberg
Journal:  Support Care Cancer       Date:  2007-10-10       Impact factor: 3.603

7.  Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.

Authors:  Hideki Takeuchi; Toshiaki Saeki; Keisuke Aiba; Kazuo Tamura; Kenjiro Aogi; Kenji Eguchi; Kenji Okita; Yoshikazu Kagami; Ryuhei Tanaka; Kazuhiko Nakagawa; Hirofumi Fujii; Narikazu Boku; Makoto Wada; Tatsuo Akechi; Yasuhiro Udagawa; Yutaka Okawa; Yusuke Onozawa; Hidenori Sasaki; Yasuo Shima; Naohito Shimoyama; Masayuki Takeda; Toshihiko Nishidate; Akifumi Yamamoto; Tadashi Ikeda; Koichi Hirata
Journal:  Int J Clin Oncol       Date:  2015-06-17       Impact factor: 3.402

8.  The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron.

Authors:  M S Aapro; V Kirchner; J P Terrey
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.